What is the role of neoadjuvant chemotherapy in the management of ovarian cancer?

ONCOLOGY

Volumn 22, Issue 10, 2008, Pages 1118-1125

  Schwartz, Peter E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PATIENT CARE; REVIEW; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 54949131704     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Winter WE 3rd, Maxell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:3621-3627, 2007.
2. Winter WE 3rd, Maxell GL, Tian C, et al: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 26:83-89, 2008.
3. Chambers JT, Chambers SK, Voynick IM, et al: Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 37:327-331, 1990.
4. Schwartz PE, Zheng W: Neoadjuvant chemotherapy for advanced ovarian cancer: The role of cytology in pretreatment diagnosis. Gynecol Oncol 90:644-650, 2003.
5. Schwartz PE: Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16:585-596, 2002.
6. Pecorelli S, Odicino F, Favalli G: Interval debulking surgery in advanced ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16:573-583, 2002.
7. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11:166-172, 1993.
8. Qayyum A, Coakley FV, Westphalen AC, et al: Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 96:301-306, 2005.
9. Byrom J, Widjaja E, Redman CWE, et al: Can preoperative computed tomography predict respectability of ovarian carcinoma at primary laparotomy? Br J Obstet Gynaecol 109:369-375, 2002.
10. Bristow RE, Duska L, Lambrou N, et al: A model for predicting surgical outcomes in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532-1540, 2000.
11. Dowdy S, Mullany S, Brandt K, et al: The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101:346-352, 2004.
12. Axtell AE, Lee MH, Bristow RE, et al: Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 25:384-389, 2007.
13. Chi DS, Venktraman ES, Masson V, et al: The ability of preoperative serum CA125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227-231, 2000.
14. Obeidat B, Latimer J, Crawford R: Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA125 level. Gynecol Obstet Invest 57:153-156, 2004.
15. Memarzadeh S, Lee SB, Berek JS, et al: CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 13:120-124, 2003.
16. Gemer O, Lurain M, Gdalevich M, et al: A multicenter study of CA125 as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 31:1006-1010, 2005.
17. Chi DS, Franklin CC, Levine DA, et al: Improved optimal cytoreduction rates for stage IIIC and IV epithelial ovarian, fallopian tube, primary peritoneal cancer: A change in surgical approach. Gynecol Oncol 94:650-654, 2004.
18. Hou JY, Kelly MG, Yu H, et al: Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105:211-217, 2007.
19. Angioli R, Palaia I, Zullo MA, et al: Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 100:455-461, 2006.
20. Deffieux C, Castaigne D, Pomel C: Role of laparoscopy to evaluated candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 16:35-40, 2006.
21. Fagotti A, Ferrandina G, Fanfani F, et al: A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study. Ann Surg Oncol 13:1156-1161, 2006.
22. Berchuck A, Iversen ES, Lancaster JM, et al: Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190:910-925, 2004.
23. Bristow RE, Eisenhauer EL, Santillan A, et al: Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104:480-490, 2007.
24. Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 103:1070-1076, 2006.
25. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996.
26. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006.
27. Eisenkop SM, Spirtos NM, Friedman RL, et al: Relative influence of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer. A prospective study. Gynecol Oncol 90:390-396, 2003.
28. Vergote I, deWever I, Tjalma W, et al: Neoadjuvant chemotherapy or primary surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71:431-436, 1998.
29. Rafii A, Deval B, Geay J-F, et al: Treatment of FIGO stage IV ovarian carcinoma: Results of primary surgery or interval surgery after neoadjuvant chemotherapy: A retrospective study. Int J Gynecol Cancer 17:777-783, 2007.
30. Eitan R, Levine DA, Abu-Rustum N, et al: The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 103:1397-1401, 2005.
31. Juretzka MM, Abu-Rustum N, Sonoda Y, et al: The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol 104:670-674, 2007.
32. Schmeler KM. Sun CC, Bodurka DC, et al: Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108:510-514, 2008.
33. Gershenson DM, Sun CC, Lu KH, et al: Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361-368, 2006.
34. Chan YM, Ng TY, Ngan H, et al: Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study. Gynecol Oncol 88:9-16, 2003.
35. Crawford SC, Vasey PA, Paul J, et al: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from and international comparison within the SCOTROC-1 trial. J Clin Oncol 23:8802-8811, 2005.
36. Onda T, Matsumoto K, Shibata T, et al: Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group study. JCO 0602. Jpn J Clin Oncol 38:74-77, 2008.
37. Le T, Faught W, Hopkins L, et al: Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer 15:770-775, 2005.
38. Aletti GD, Dowdy SC, Podratz KC, et al: Analysis of factors impacting operability in stage IV ovarian cancer. Rationale use of a triage system. Gynecol Oncol 105:84-89, 2007.
39. Tiersten A, Liu P, Smith H, et al: Phase II evaluation of neoadjuvant chemotherapy and interval debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube, or primary peritoneal cancer: A Southwest Oncology Group study (abstract 3). Presented at the 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, Fla, March 9, 2008. Gynecol Oncol 108:S3, 2008.
40. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Mongr 421:101-104, 1975.
41. Rossi DJ, Jamieson CHM, Weissman IL: Stem cells and the pathways to aging and cancer. Cell 132:681-696, 2008.